Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer

John R. Murren, Henry J. Durivage, Antonio C. Buzaid, Michael Reiss, Stuart D Flynn, Darryl Carter, William N. Hait

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Overexpression of P-glycoprotein (P-gp) has been implicated as the mechanism of multidrug resistance (MDR) in a number of human cancers, including carcinoma of the breast. We conducted a clinical trial to determine whether the P-gp inhibitor, trifluoperazine, could sensitize patients with refractory breast cancer to vinblastine chemotherapy. Adult patients with histologically confirmed, refractory, advanced breast cancer were treated with vinblastine at a dose of 1.7 mg/m2 per day by continuous infusion for five consecutive days. Patients who did not respond after two cycles were subsequently treated with vinblastine plus trifluoperazine at a dose of 8 mg twice daily during the five days of chemotherapy. In patients from whom tumor samples were available, the expression of P-gp was determined by immunocytochemistry. Of 35 patients enrolled, 30 were evaluable, 2 of whom (7%) achieved a partial response to vinblastine alone. Among the 16 patients treated with vinblastine plus trifluoperazine there was one response (6%) which lasted 16 weeks. Tumor samples were available from 16 patients, and 14 (87%) were immunoreactive for P-gp. P-gp expression was detected both in the patient who responded to vinblastine plus trifloperazine and in one of the two patients who responded to vinblastine alone. Continuous-infusion vinblastine demonstrated limited activity in this study. Furthermore, trifluoperazine did not effectively reverse established resistance to vinblastine. This failure may be related the presence of multiple mechanisms of drug resistance in this heavily pretreated population, or because ineffective concentrations of the modulator were achieved in vivo. Future studies should evaluate more effective modulators, and attempt to reverse MDR earlier in the course of treatment, before other forms of resistance can develop.

Original languageEnglish (US)
Pages (from-to)65-70
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume38
Issue number1
StatePublished - 1996
Externally publishedYes

Fingerprint

Trifluoperazine
Vinblastine
Multiple Drug Resistance
Refractory materials
Modulators
Breast Neoplasms
P-Glycoprotein
Chemotherapy
Tumors
Drug Therapy
Neoplasms
Immunohistochemistry
Clinical Trials

Keywords

  • Breast cancer
  • Multidrug resistance
  • Trifluoperazine
  • Vinblastine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Murren, J. R., Durivage, H. J., Buzaid, A. C., Reiss, M., Flynn, S. D., Carter, D., & Hait, W. N. (1996). Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. Cancer Chemotherapy and Pharmacology, 38(1), 65-70.

Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. / Murren, John R.; Durivage, Henry J.; Buzaid, Antonio C.; Reiss, Michael; Flynn, Stuart D; Carter, Darryl; Hait, William N.

In: Cancer Chemotherapy and Pharmacology, Vol. 38, No. 1, 1996, p. 65-70.

Research output: Contribution to journalArticle

Murren, JR, Durivage, HJ, Buzaid, AC, Reiss, M, Flynn, SD, Carter, D & Hait, WN 1996, 'Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer', Cancer Chemotherapy and Pharmacology, vol. 38, no. 1, pp. 65-70.
Murren, John R. ; Durivage, Henry J. ; Buzaid, Antonio C. ; Reiss, Michael ; Flynn, Stuart D ; Carter, Darryl ; Hait, William N. / Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. In: Cancer Chemotherapy and Pharmacology. 1996 ; Vol. 38, No. 1. pp. 65-70.
@article{952529b13acb4f0ab7737f85624b3783,
title = "Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer",
abstract = "Overexpression of P-glycoprotein (P-gp) has been implicated as the mechanism of multidrug resistance (MDR) in a number of human cancers, including carcinoma of the breast. We conducted a clinical trial to determine whether the P-gp inhibitor, trifluoperazine, could sensitize patients with refractory breast cancer to vinblastine chemotherapy. Adult patients with histologically confirmed, refractory, advanced breast cancer were treated with vinblastine at a dose of 1.7 mg/m2 per day by continuous infusion for five consecutive days. Patients who did not respond after two cycles were subsequently treated with vinblastine plus trifluoperazine at a dose of 8 mg twice daily during the five days of chemotherapy. In patients from whom tumor samples were available, the expression of P-gp was determined by immunocytochemistry. Of 35 patients enrolled, 30 were evaluable, 2 of whom (7{\%}) achieved a partial response to vinblastine alone. Among the 16 patients treated with vinblastine plus trifluoperazine there was one response (6{\%}) which lasted 16 weeks. Tumor samples were available from 16 patients, and 14 (87{\%}) were immunoreactive for P-gp. P-gp expression was detected both in the patient who responded to vinblastine plus trifloperazine and in one of the two patients who responded to vinblastine alone. Continuous-infusion vinblastine demonstrated limited activity in this study. Furthermore, trifluoperazine did not effectively reverse established resistance to vinblastine. This failure may be related the presence of multiple mechanisms of drug resistance in this heavily pretreated population, or because ineffective concentrations of the modulator were achieved in vivo. Future studies should evaluate more effective modulators, and attempt to reverse MDR earlier in the course of treatment, before other forms of resistance can develop.",
keywords = "Breast cancer, Multidrug resistance, Trifluoperazine, Vinblastine",
author = "Murren, {John R.} and Durivage, {Henry J.} and Buzaid, {Antonio C.} and Michael Reiss and Flynn, {Stuart D} and Darryl Carter and Hait, {William N.}",
year = "1996",
language = "English (US)",
volume = "38",
pages = "65--70",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer

AU - Murren, John R.

AU - Durivage, Henry J.

AU - Buzaid, Antonio C.

AU - Reiss, Michael

AU - Flynn, Stuart D

AU - Carter, Darryl

AU - Hait, William N.

PY - 1996

Y1 - 1996

N2 - Overexpression of P-glycoprotein (P-gp) has been implicated as the mechanism of multidrug resistance (MDR) in a number of human cancers, including carcinoma of the breast. We conducted a clinical trial to determine whether the P-gp inhibitor, trifluoperazine, could sensitize patients with refractory breast cancer to vinblastine chemotherapy. Adult patients with histologically confirmed, refractory, advanced breast cancer were treated with vinblastine at a dose of 1.7 mg/m2 per day by continuous infusion for five consecutive days. Patients who did not respond after two cycles were subsequently treated with vinblastine plus trifluoperazine at a dose of 8 mg twice daily during the five days of chemotherapy. In patients from whom tumor samples were available, the expression of P-gp was determined by immunocytochemistry. Of 35 patients enrolled, 30 were evaluable, 2 of whom (7%) achieved a partial response to vinblastine alone. Among the 16 patients treated with vinblastine plus trifluoperazine there was one response (6%) which lasted 16 weeks. Tumor samples were available from 16 patients, and 14 (87%) were immunoreactive for P-gp. P-gp expression was detected both in the patient who responded to vinblastine plus trifloperazine and in one of the two patients who responded to vinblastine alone. Continuous-infusion vinblastine demonstrated limited activity in this study. Furthermore, trifluoperazine did not effectively reverse established resistance to vinblastine. This failure may be related the presence of multiple mechanisms of drug resistance in this heavily pretreated population, or because ineffective concentrations of the modulator were achieved in vivo. Future studies should evaluate more effective modulators, and attempt to reverse MDR earlier in the course of treatment, before other forms of resistance can develop.

AB - Overexpression of P-glycoprotein (P-gp) has been implicated as the mechanism of multidrug resistance (MDR) in a number of human cancers, including carcinoma of the breast. We conducted a clinical trial to determine whether the P-gp inhibitor, trifluoperazine, could sensitize patients with refractory breast cancer to vinblastine chemotherapy. Adult patients with histologically confirmed, refractory, advanced breast cancer were treated with vinblastine at a dose of 1.7 mg/m2 per day by continuous infusion for five consecutive days. Patients who did not respond after two cycles were subsequently treated with vinblastine plus trifluoperazine at a dose of 8 mg twice daily during the five days of chemotherapy. In patients from whom tumor samples were available, the expression of P-gp was determined by immunocytochemistry. Of 35 patients enrolled, 30 were evaluable, 2 of whom (7%) achieved a partial response to vinblastine alone. Among the 16 patients treated with vinblastine plus trifluoperazine there was one response (6%) which lasted 16 weeks. Tumor samples were available from 16 patients, and 14 (87%) were immunoreactive for P-gp. P-gp expression was detected both in the patient who responded to vinblastine plus trifloperazine and in one of the two patients who responded to vinblastine alone. Continuous-infusion vinblastine demonstrated limited activity in this study. Furthermore, trifluoperazine did not effectively reverse established resistance to vinblastine. This failure may be related the presence of multiple mechanisms of drug resistance in this heavily pretreated population, or because ineffective concentrations of the modulator were achieved in vivo. Future studies should evaluate more effective modulators, and attempt to reverse MDR earlier in the course of treatment, before other forms of resistance can develop.

KW - Breast cancer

KW - Multidrug resistance

KW - Trifluoperazine

KW - Vinblastine

UR - http://www.scopus.com/inward/record.url?scp=0029917474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029917474&partnerID=8YFLogxK

M3 - Article

C2 - 8603454

AN - SCOPUS:0029917474

VL - 38

SP - 65

EP - 70

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -